Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985313 | 0.82 | F2 (0.47) | EPHX2EPHX1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL19712313 | 0.81 | EPHX2 (0.40) | EPHX2EPHX1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL19712342 | 0.80 | HSD17B10 (0.44) | EPHX2EPHX1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL27660924 | 0.80 | EPHX2 (0.53) | EPHX2EPHX1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL19712315 | 0.79 | EPHX2 (0.38) | EPHX2EPHX1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6164078 | 0.77 | TP53 (0.53) | EPHX2EPHX1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL3397254 | 0.77 | EPHX2 (1.00) | EPHX2EPHX1RAB9ANPC1HPGD | |
| SCHEMBL5051924 | 0.77 | EPHX2 (1.00) | EPHX2EPHX1RAB9ANPC1HPGD | |
| SCHEMBL27640143 | 0.76 | RAB9A (0.50) | EPHX2EPHX1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6166503 | 0.76 | TP53 (0.51) | EPHX2EPHX1RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501937-B2 | Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-06 | — | — | US | disclosed |
| US-20120184737-A1 | METHOD OF PRODUCING HIGHLY FUNCTIONALIZED 1,3-DIAMINO-PROPAN-2-OLS FROM SOLID SUPPORT | COATS STEVE J (US) | 2012-07-19 | — | — | US | disclosed |
| US-8168826-B2 | Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support | Janssen Pharamcuetica N.V. (BE) | 2012-05-01 | — | — | US | disclosed |
| US-20100081806-A1 | METHOD OF PRODUCING HIGHLY FUNCTIONALIZED 1,3-DIAMINO-PROPAN-2-OLS FROM SOLID SUPPORT | COATS STEVE J | 2010-04-01 | — | — | US | disclosed |
| US-7649055-B2 | Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20080281095-A1 | METHOD OF PRODUCING HIGHLY FUNCTIONALIZED 1,3-DIAMINO-PROPAN-2-OLS FROM SOLID SUPPORT | COATS STEVE J | 2008-11-13 | — | — | US | disclosed |
| US-7408008-B2 | Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-05 | — | — | US | disclosed |
| CN-101128421-A | Methods and compositions for treating amyloid-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-02-20 | — | — | CN | disclosed |
| US-20050124001-A1 | Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support | ULTRA CLEAN HOLDINGS, INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281095-A1 | METHOD OF PRODUCING HIGHLY FUNCTIONALIZED 1,3-DIAMINO-PROPAN-2-OLS FROM SOLID SUPPORT | HPN, DNPEP, PEPD | EPHX2 535/4885EPHX1 399/4885RAB9A 4233/4885 |
| US-20100081806-A1 | METHOD OF PRODUCING HIGHLY FUNCTIONALIZED 1,3-DIAMINO-PROPAN-2-OLS FROM SOLID SUPPORT | HPN, DNPEP, PEPD | EPHX2 535/4885EPHX1 399/4885RAB9A 4233/4885 |
| US-20120184737-A1 | METHOD OF PRODUCING HIGHLY FUNCTIONALIZED 1,3-DIAMINO-PROPAN-2-OLS FROM SOLID SUPPORT | HPN, DNPEP, PEPD | EPHX2 535/4885EPHX1 399/4885RAB9A 4233/4885 |
| US-20050124001-A1 | Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support | HPN, DNPEP, PEPD | EPHX2 535/4885EPHX1 399/4885RAB9A 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.